Peptide Glow Journal

sh-Oligopeptide-1: A 53-Residue Growth Factor Declared as an Oligopeptide

sh-Oligopeptide-1 is recombinant human EGF. It is 53 amino acids and about 6,222 daltons — and a 2023 toxicology paper asks whether the clinical trials citing it are risk or fraud.

Fiona G · Edited by Caroline S · Published 2026-09-20

Illustration: A golden serum drop hovers above textured beige linen, illuminated by soft morning light.
Illustration

Most ingredient entries on this site begin by explaining what a peptide is claimed to do. This one begins by saying what the ingredient is, because the name actively obscures it.

sh-Oligopeptide-1 is recombinant human epidermal growth factor. It is not a short synthetic peptide of the kind listed around it on a label. It is a growth factor — a signalling protein — and the cosmetic naming convention files it under oligopeptide.

The size

Human EGF is produced as a large precursor and cut down. In UniProt P01133, the pro-epidermal growth factor precursor runs to 1,207 residues; the mature EGF chain is residues 971 to 1,023, which is 53 amino acids. Calculated from that sequence, its average mass is about 6,222 daltons.

Set that beside the peptides it shares a shelf with:

Ingredient Residues Approximate mass
Copper tripeptide-1 3 402.9 Da
Pentapeptide-18 5 569.6 Da
Acetyl hexapeptide-8 6 887.0 Da
Nonapeptide-1 9 1,206.5 Da
sh-Oligopeptide-1 (EGF) 53 ~6,222 Da

An oligopeptide, by ordinary usage, is a short chain — commonly taken to mean fewer than about twenty residues. Fifty-three residues and six kilodaltons is a small protein. The naming is permitted and it is not a deception, but it places a growth factor in the same nomenclature family as a tripeptide, and a reader scanning an ingredient list has no way to tell them apart.

The consequence for penetration is arithmetic. The 500-dalton heuristic that dominates every discussion of cosmetic peptides puts the practical ceiling for passive movement across intact stratum corneum at around 500 Da. This molecule is more than twelve times that.

Two literatures under one molecule

Here the numbers diverge sharply. Searched on 2026-09-20:

  • sh-oligopeptide-1 in the title or abstract: 3 records.
  • epidermal growth factor + skin, typed as randomized controlled trials: 129 records.

The second number is the one quoted in marketing, and it is real. It is also, read through, largely a wound-care and oncology-supportive literature — diabetic foot ulcers, burns, surgical wounds, radiation dermatitis. Those are settings where the barrier is already breached and where a growth factor is being used as a drug, under prescription, at defined doses. It is not a literature about a serum on intact facial skin.

The three records under the cosmetic name are:

  1. a 2025 Gels study of an emulgel for atopic dermatitis, investigated clinically in children;
  2. a 2023 BMC Musculoskeletal Disorders single-arm pre-market investigation of a topical lotion based on hyaluronic acid and peptides;
  3. a 2023 review in Cutaneous and Ocular Toxicology — which is where this entry has to slow down.

The first two are multi-ingredient products in single-arm or clinical-investigation designs, so neither isolates what sh-oligopeptide-1 contributes.

The 2023 paper, and what it actually claims

The title is not subtle: Topical application of sh-oligopeptide-1 and clinical trials with cosmetic preparations: risk or fraud?, by P. A. Martínez-Carpio of a clinical trials unit in Sabadell, Spain, published in Cutaneous and Ocular Toxicology 2023;42(4):190-197.

Its method, as stated: a specialised search of Medline and Google Scholar in March 2023 returning 22 references, of which 12 articles were selected for analysis and 7 were Medline-indexed; nine of them use sh-oligopeptide-1 as equivalent to functional recombinant human EGF. The author then investigated the manufacturers and requested scientific information from them.

Its stated conclusions, attributed to that author:

  • sh-oligopeptide-1 is not a functional EGF, and its preclinical bioactivity has not been proven;
  • clinical studies using it as an EGF equivalent therefore have no scientific basis;
  • active EGF is not a cosmetic but "a potent unauthorised drug", and topical recombinant human EGF is not authorised as a medication at any concentration outside clinical trials;
  • meanwhile sh-oligopeptide-1 is authorised as a cosmetic at several different concentrations for general use, with unknown long-term risks.

This is a single-author review in a peer-reviewed toxicology journal, and it is the strongest statement in the indexed record about this ingredient. We have looked for a published reply or rebuttal and have not found one; the absence of a reply is not agreement, and readers should weigh it as one carefully argued position rather than as a settled consensus.

What makes it unusually relevant to a shopper is that both halves of its argument are checkable on any label. If the ingredient is inactive, the trials citing it cannot mean what they say. If it is active, it is a growth factor being applied without the supervision a growth factor normally carries. The paper's discomfort is that the same molecule is being described both ways by different people in the same market.

What the evidence supports saying

  • sh-Oligopeptide-1 is recombinant human EGF, a 53-residue protein of about 6,222 daltons, whatever the INCI name suggests.
  • The large EGF clinical literature is mostly wound care and oncology support, not cosmetic anti-ageing, and it is applied to skin whose barrier is already compromised.
  • Three papers name the cosmetic ingredient; two of them test it inside a mixture, and the third questions the basis of the rest.
  • Its size puts it far beyond the range in which passive penetration of intact skin is usually considered plausible, which is why products containing it lean on delivery systems or on post-procedure use.

None of that is a statement about any particular product, and this page makes none.

Where to go next

Sources

Frequently asked questions

What is sh-oligopeptide-1?

It is the cosmetic ingredient name for recombinant human epidermal growth factor, EGF. The 'sh' prefix denotes a synthetic or recombinant human sequence. Mature human EGF is 53 amino acids long, cut out of a 1,207-residue precursor protein, and weighs about 6,222 daltons.

Is it really a peptide?

It sits at the boundary, and the INCI name pushes it to the wrong side of it. An oligopeptide usually means a chain of roughly twenty residues or fewer. Fifty-three residues and six kilodaltons is normally described as a small protein or a growth factor. Nothing about the naming is against the rules; it just makes the ingredient sound like the small synthetic peptides it is listed beside, and it is about fifteen times their size.

How much evidence is there for it?

Three PubMed records under the cosmetic name on 2026-09-20. Two of them test it inside multi-ingredient products — an atopic dermatitis emulgel for children and a hyaluronic-acid lotion in a single-arm pre-market study — so neither isolates the ingredient. The third is a 2023 review in a toxicology journal that examines the whole set of studies and questions their basis.

What does the 2023 review say?

Martinez-Carpio, writing in Cutaneous and Ocular Toxicology, searched the literature in March 2023, analysed twelve articles and wrote to manufacturers for data. The paper's stated conclusions are that sh-oligopeptide-1 is not a functional EGF, that its preclinical bioactivity has not been proven, and that clinical studies using it as an equivalent to recombinant human EGF have no scientific basis. It also notes that active topical EGF is an unauthorised drug, while sh-oligopeptide-1 is authorised as a cosmetic at various concentrations with unknown long-term risks. Those are one author's conclusions in a peer-reviewed toxicology journal, and we have not found a published reply to them.

But EGF has hundreds of studies — doesn't that count?

PubMed held 129 records typed as randomized controlled trials for epidermal growth factor and skin on 2026-09-20, which is a substantial literature. It is also mostly the wrong literature for a serum: diabetic foot ulcers, burns, radiation dermatitis and surgical wounds, where the barrier is already broken and a growth factor can reach the tissue. Citing that body of work for a cosmetic applied to intact skin is the transfer the 2023 review objects to.

Can a 6,222-dalton molecule get into skin?

Not passively, on the usual heuristic. The 500-dalton rule holds that compounds much above 500 daltons do not cross intact stratum corneum in useful amounts; this one is more than twelve times that. Products containing it typically pair it with delivery systems, or are positioned for use after microneedling or a procedure — which is a different situation, because the barrier is no longer intact.

Is it the same thing as a growth factor serum?

Usually yes. Products marketed as growth factor serums commonly declare sh-oligopeptide-1, and sometimes related sh- names for other growth factors. The word peptide on the front of the box and the word oligopeptide in the ingredient list both point away from what the ingredient is, which is why this entry names it in the first line.